NO20054351D0 - Monoklonalt antistoff og hybridom som produserer dette - Google Patents

Monoklonalt antistoff og hybridom som produserer dette

Info

Publication number
NO20054351D0
NO20054351D0 NO20054351A NO20054351A NO20054351D0 NO 20054351 D0 NO20054351 D0 NO 20054351D0 NO 20054351 A NO20054351 A NO 20054351A NO 20054351 A NO20054351 A NO 20054351A NO 20054351 D0 NO20054351 D0 NO 20054351D0
Authority
NO
Norway
Prior art keywords
monoclonal antibody
hybridoma producing
hybridoma
producing
monoclonal
Prior art date
Application number
NO20054351A
Other languages
English (en)
Other versions
NO20054351L (no
Inventor
Toshi Komurasaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of NO20054351D0 publication Critical patent/NO20054351D0/no
Publication of NO20054351L publication Critical patent/NO20054351L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20054351A 2003-03-14 2005-09-20 Monoklonalt antistoff og hybridom som produserer dette NO20054351L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003070864 2003-03-14
PCT/JP2004/003424 WO2004081047A1 (ja) 2003-03-14 2004-03-15 モノクローナル抗体及びこれを産生するハイブリドーマ

Publications (2)

Publication Number Publication Date
NO20054351D0 true NO20054351D0 (no) 2005-09-20
NO20054351L NO20054351L (no) 2005-11-28

Family

ID=32984673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054351A NO20054351L (no) 2003-03-14 2005-09-20 Monoklonalt antistoff og hybridom som produserer dette

Country Status (11)

Country Link
US (1) US7435590B2 (no)
EP (1) EP1607404A4 (no)
JP (1) JPWO2004081047A1 (no)
KR (1) KR20050108389A (no)
CN (1) CN1761682A (no)
AU (1) AU2004220156B2 (no)
CA (1) CA2519105A1 (no)
MX (1) MXPA05009751A (no)
NO (1) NO20054351L (no)
RU (1) RU2312109C2 (no)
WO (1) WO2004081047A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399766T1 (de) * 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
CN101337930B (zh) * 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CA2627598C (en) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
US8865737B2 (en) * 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
NZ601022A (en) * 2006-10-12 2014-09-26 Chugai Pharmaceutical Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
AU2012261543B2 (en) * 2006-10-12 2016-05-26 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
JP5319306B2 (ja) * 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
ES2831573T3 (es) 2009-04-27 2021-06-08 Becton Dickinson Co Dispositivo de preparación de muestras y método asociado
WO2010137654A1 (ja) 2009-05-29 2010-12-02 株式会社未来創薬研究所 Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
EP3434694B1 (en) * 2010-04-09 2020-12-30 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
AU2012248158C1 (en) * 2011-04-28 2017-02-02 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100313736B1 (ko) 1993-06-04 2002-03-21 우에하라 아끼라 사람유래종양세포증식저해인자
JP2001149079A (ja) * 1999-11-26 2001-06-05 Japan Science & Technology Corp 新規の増殖因子タンパク質および該タンパク質をコードする遺伝子
CA2418496A1 (en) 2000-02-24 2001-08-30 Incyte Genomics, Inc. Secretory polypeptides and corresponding polynucleotides
AU2001269766A1 (en) * 2000-06-09 2001-12-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
AU2004220156B2 (en) 2007-04-19
KR20050108389A (ko) 2005-11-16
MXPA05009751A (es) 2005-10-26
EP1607404A1 (en) 2005-12-21
CN1761682A (zh) 2006-04-19
CA2519105A1 (en) 2004-09-23
RU2312109C2 (ru) 2007-12-10
AU2004220156A1 (en) 2004-09-23
RU2005131842A (ru) 2006-02-10
US7435590B2 (en) 2008-10-14
WO2004081047A1 (ja) 2004-09-23
NO20054351L (no) 2005-11-28
EP1607404A4 (en) 2008-01-23
US20060252105A1 (en) 2006-11-09
JPWO2004081047A1 (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
NO20054351D0 (no) Monoklonalt antistoff og hybridom som produserer dette
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IL184152A0 (en) Monoclonal antibodies against nkg2a
IL191217A (en) Anti-17 mantle monoclonal antibody
DK1501856T3 (da) Anti-HER2 antistofvarianter
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
EP1761566A4 (en) HUMANIZED MONOCLONAL ANTIBODIES ANTI-TAG-72
IL172871A (en) Isolated human antibody or antigen-binding section, training linker, single-chain antibody molecule, polypeptide containing them and their use
DE60334076D1 (de) Monoklonaler anti-mensch-tenascin-Antikörper
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
HK1098825A1 (en) Human monoclonal antibodies against cd20
EP1572077A4 (en) USES OF MONOCLONAL 8H9 ANTIBODIES
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
BRPI0509495A2 (pt) anticorpo humanizado
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
ZA200706185B (en) Monoclonal antibodies against NKG2A
EP1820855A4 (en) MONOCLONAL ANTI-HISTON-H1 ANTIBODY AND ITS MANUFACTURE OF HYBRIDOMA
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
EP1545430A4 (en) BISPECIFIC MOLECULE COMPRISING ANTI-CR1TICTIC ANTIBODY TO ANTIGENIC BINDING ANTIBODY FRAGMENT
EP1841782A4 (en) MONOCLONAL ANTITENASCIN ANTIBODY IMMUNOTESTS AND DIAGNOSIS KITS
ITRM20040105A1 (it) Anticorpo monoclonale antitenascina umana.
DE112004002660D2 (de) Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1712564A4 (en) MONOCLONAL ANTIBODY ANTI-NC1
FI20011055A (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application